A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in platinum-resistant ovarian cancer.

被引：2
|
作者：
Garcia, Agustin A.
Hays, John L.
Cote, Gregory Michael
Becerra, Carlos
Langleben, Adrian
Lau, Susie K.
Roman, Lynda D.
McCormick, Colleen Catherine
Richards, Donald A.
Braiteh, Fadi S.
Yimer, Habte Aragaw
Richey, Stephen Lane
Edenfield, William Jeffery
Kossler, Kimiko
Hume, Stephanie
Li, Youzhi
Hitron, Matthew
Li, Chiang
机构：
[1] Univ Southern Calif, Los Angeles Cty Hosp, Los Angeles, CA USA
[2] Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Texas Oncol Baylor Charles Sammons Canc Ctr, Dallas, TX USA
[5] St Marys Hosp, Westmount, PQ, Canada
[6] McGill Univ, Montreal, PQ, Canada
[7] Johns Hopkins Univ Hosp, Portland, OR USA
[8] McKesson Specialty Hlth, Tyler Canc Ctr, US Oncol Res, Houston, TX USA
[9] McKesson Specialty Hlth, US Oncol Network, The Woodlands, TX USA
[10] Texas Oncol, Tyler, TX USA
[11] McKesson Specialty Hlth, Texas Oncol, US Oncol Network, Houston, TX USA
[12] Univ Med Ctr, Greenville Hosp Syst, Inst Translat Oncol Res, Greenville, SC USA
[13] Boston Biomed Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5578
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A Phase Ib/II Study of Cancer Sternness Inhibitor Napabucasin (BB608) Combined with Weekly Paclitaxel in Advanced Triple Negative Breast Cancer.
    Becerra, Carlos
    Braiteh, Fadi S.
    Spira, Alexander I.
    Langleben, Adrian
    Panasci, Lawrence C.
    Vukelja, Svetislava J.
    Hinshaw, Ioana M.
    Goodwin, Rachel Anne
    Panella, Timothy J.
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [2] A phase Ib/II study of cancer sternness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.
    Becerra, Carlos
    Spira, Alexander I.
    Conkling, Paul R.
    Richey, Stephen Lane
    Hanna, Wahid Tewfik
    Cote, Gregory Michael
    Heist, Rebecca Suk
    Langleben, Adrian
    Laurie, Scott Andrew
    Edenfield, William Jeffery
    Kossler, Kimiko
    Hume, Stephanie
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [3] A phase Ib extension study of cancer sternness inhibitor BB608 (napabucasin) in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic cancer.
    El-Rayes, Bassel F.
    Shanda, Safi
    Starodub, Alexander
    O'Neil, Bert H.
    Hanna, Wahid Tewfik
    Shaib, Walid Labib
    Oh, Cindy
    Li, Wei
    Li, Youzhi
    Borodyansky, Laura
    Li, Chiang
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] Phase II study of gemcitabine and weekly paclitaxel in recurrent platinum-resistant ovarian cancer
    Garcia, AA
    O'Meara, A
    Bahador, A
    Facio, G
    Jeffers, S
    Kim, DY
    Roman, L
    GYNECOLOGIC ONCOLOGY, 2004, 93 (02) : 493 - 498
  • [5] A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.
    Bekaii-Saab, Tanios S.
    Mikhail, Sameh
    Langleben, Adrian
    Becerra, Carlos
    Jonker, Derek J.
    Asmis, Timothy R.
    Cote, Gregory Michael
    Wu, Christina Sing-Ying
    Kwak, Eunice Lee
    Spira, Alexander I.
    Braiteh, Fadi S.
    Richey, Stephen Lane
    Hume, Stephanie
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [6] A phase Ib/II study of rebastinib and paclitaxel in advanced/metastatic platinum-resistant ovarian cancer
    Hamilton, E. P.
    Goel, S.
    Arend, R.
    Chu, C.
    Richardson, D. L.
    Corr, B.
    John, V.
    Janku, F.
    Hays, J.
    Michenzie, M.
    Reichmann, W.
    Achour, H.
    Sherman, M. L.
    Ruiz-Soto, R.
    Mathews, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S731 - S732
  • [7] A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer
    Hamilton, E. P.
    Goel, S.
    Arend, R.
    Chu, C.
    Richardson, D. L.
    Diamond, J. R.
    John, V.
    Janku, F.
    Matthews, C.
    JeBailey, L.
    Kuida, K.
    Achour, H.
    Ruiz-Soto, R.
    Hays, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S629 - S630
  • [8] A phase 1 study of the SYK inhibitor fostamatinib and weekly paclitaxel for recurrent platinum-resistant ovarian cancer
    Gaillard, Stephanie
    Wilkinson, Mary
    Martin, Lainie P.
    Deery, Amy
    Langsdale, Amanda
    Bayable, Asnakech
    Zahurak, Marianna
    Huang, Peng
    Armstrong, Deborah Kay
    Shih, Ie-Ming
    Wang, Tian-Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [9] A phase 1b/2 study of napabucasin with weekly paclitaxel in advanced, previously treated platinum resistant ovarian cancer.
    Becerra, Carlos
    Garcia, Agustin A.
    Hays, John L.
    Method, Michael W.
    Richey, Stephen Lane
    Langleben, Adrian
    Richards, Donald A.
    Cote, Gregory Michael
    Kossler, Kimiko
    Li, Wei
    Li, Youzhi
    Hitron, Matthew
    Li, Chiang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Weekly gemcitabine in patients with relapsed platinum-resistant ovarian or peritoneal cancer. Results of phase II study
    Czerniawska, Malgorzata
    Jagiello-Gruszfeld, Agnieszka
    Zbrzezniak, Jolanta
    Wachula, Ewa
    Szablowska-Siwik, Sylwia
    Sikorska, Magdalena
    ANNALS OF ONCOLOGY, 2006, 17 : 172 - 172
12345